Assessment of Lateral Geniculate Nucleus Atrophy with 3T MR Imaging and Correlation with Clinical Stage of Glaucoma


AJNR Am J Neuroradiol 2011, 32 (7) 1347-1353
doi: https://doi.org/10.3174/ajnr.A2486
http://www.ajnr.org/content/32/7/1347
Assessment of Lateral Geniculate Nucleus Atrophy with 3T MR Imaging and Correlation with Clinical Stage of Glaucoma

**BACKGROUND AND PURPOSE:** Although previous animal studies have shown structural changes in ocular hypertension such as atrophy of the LGN, such changes have not been thoroughly studied in human glaucoma patients nor correlation made with clinical stage. Our aim was to investigate prospectively LGN atrophy in patients with POAG using 3T MR imaging and correlation with the clinical stage of disease.

**MATERIALS AND METHODS:** Twenty-six patients with known POAG and 26 age-matched healthy volunteers were included in this institutional review board–approved study. All subjects underwent imaging on a 3T MR imaging system with a PD and GM sequence. LGN height and volume were measured by 2 blinded neuroradiologists. Measurements were compared and correlated with clinical glaucoma severity as assessed by static threshold visual field parameters.

**RESULTS:** Average maximum LGN height in patients with glaucoma on PD images was 4.36 ± 0.61 mm (right) and 4.31 ± 0.61 mm (left), significantly less (P < 10^{-3}) than respective measurements of 5.05 ± 0.41 and 4.99 ± 0.41 mm in volunteers. With the GM sequences, such respective measurements were also less (P < 10^{-5}) in patients with glaucoma (4.20 ± 0.71 mm right, 4.00 ± 0.85 mm left) versus respective measurements in volunteers (4.88 ± 0.51 mm right, 4.77 ± 0.47 mm left). Average LGN volumes in the patient group were 98.0 ± 27.2 mm^3 (right) and 93.7 ± 25.8 mm^3 (left) with the PD sequence versus respective measurements of 85.2 ± 27.1 and 80.5 ± 23.6 mm^3 with the GM sequence. All height and volume measurements were greater in volunteers (P < 10^{-5}). In the patient group, both maximum height and volume of the LGN with both sequences were significantly correlated with cumulative clinical glaucoma stage (P < .05).

**CONCLUSIONS:** MR imaging measurements of LGN height and volume are diminished in patients with glaucoma, with the extent of atrophy correlating to clinical stage, suggesting a novel imaging marker of disease severity.

**ABBREVIATIONS:** BRAVO = brain volume imaging; FA = fractional anisotropy; fMRI = functional MR imaging; GM = gray matter; GMhL = maximum height of the left LGN with the GM sequence; GMhR = maximum height of the right LGN with the GM sequence; GMvL = maximum volume of the left LGN with the GM sequence; GMvR = maximum volume of the right LGN with the GM sequence; LGN = lateral geniculate nucleus; MD = mean diffusivity; MDS = mean deviation score; PD = proton density; PDhL = maximum height of the left LGN with the PD sequence; PDhR = maximum height of the right LGN with the PD sequence; PDvL = volume of the left LGN with the PD sequence; PDvR = volume of the right LGN with the PD sequence; POAG = primary open-angle glaucoma; stage A = the sum of the clinical stages of both eyes; stage L = the clinical stage of the left eye of a patient with POAG; stage R = the clinical stage of the right eye of a patient with POAG; Sum = the summation of height and volume bilaterally.
glaucoma, demonstrating degenerative changes in the brain involving the intracranial optic nerves, LGN, and visual cortex in 2006. Three years later in vivo MR imaging evidence of LGN degeneration in human glaucoma was found, which was consistent with ex vivo primate and human neuropathologic studies. The aim of the present study was to further examine the MR imaging appearance of human glaucoma by correlating the stage of disease with the degree of LGN atrophy.

Materials and Methods
From March 2010 to August 2010, 2 groups of participants were included in this institutional review board–approved prospective study: a group of patients with glaucoma and a control group of healthy volunteers. Informed consent was obtained from all participants. Cardiovascular disease, diabetes, head trauma, and neurologic illness were excluded in both the POAG and control groups.

Glaucoma Group and Classification
The glaucoma group consisted of 26 patients with ages ranging from 21 to 58 years (mean, 35.4 years) with a diagnosis of POAG. This diagnosis was made on a clinical basis through assessment of the open anterior chamber angle, identification of visual field defects typical of glaucoma, optic disc cupping, or identification of an intraocular pressure of ≥21 mm Hg. In total, 21 male patients (range, 22–53 years of age; mean age, 34.4 years) and 5 female patients (range, 22–53 years of age; mean age, 39.6 years) were included in the study.

The Hodapp-Anderson-Parrish system was used to stage the eyes of all patients with glaucoma (stages 0–5). Stage 0 was characterized by increased intraocular pressure without evidence of visual field defects and with an MDS of ≥0 dB. Stage 1 (early) glaucoma was characterized by an MDS of −0.01 to −6.00 dB; stage 2 (moderate), by an MDS of −6.01 to −12.00 dB; and stage 3 (advanced) glaucoma, by an MDS of −12.01 to −20.00 dB. Stage 4 (severe) glaucoma was characterized by an MDS less than −20.01 dB. For patients designated clinically as having stage 5, static threshold perimetry was not performed. A detailed accounting of eyes (n = 52) enrolled and their categorization by clinical stage is provided in the pie chart (Fig 1).

Control Group
The control group consisted of 26 healthy individuals with ages ranging from 21 to 57 years (mean, 35.4 years) who were matched by age and sex to the patient group. Twenty-one men (age range, 21–57 years; mean, 34.5 years) and 5 women (age range, 22–55 years; mean, 38.6 years) were included as controls. All control subjects underwent an ophthalmologic examination via visual field testing to exclude glaucoma and other ocular diseases. There were no significant differences between the mean ages of the patient and control groups (P = .8).

MR Imaging
All patients were scanned with a 3T MR imaging system (Signa HDxt; GE Healthcare, Milwaukee, Wisconsin). An 8-channel phased-array head coil was used for signal-intensity acquisition. Each subject was scanned head-first and supine. To reduce patient motion, the head position was fixed with foam cushions on both sides. The following sequences were acquired: an axial 3D BRAVO sequence (TR/TE/TI, 6.8/3.5/380 ms; section thickness, 1 mm without intersection gaps; matrix, 256 × 256; FOV, 256 mm²; in-plane resolution, 1 mm; NEX, 4; bandwidth, 42 Hz; flip angle, 15°), an oblique coronal fast spin-echo PD-weighted sequence (TR/TE, 3400/22 ms; section thickness, 1.8 mm; matrix, 320 × 320; FOV, 256 mm²; in-plane resolution, 0.64 mm; NEX, 4; bandwidth, 50 Hz; echo-train length, 26), and an oblique coronal sequence with parameters designed for optimization of GM visualization (TR/TE/TI, 7600/24/300 ms; section thickness, 1.8 mm without intersection gaps; matrix, 320 × 320; FOV, 256 mm²; in-plane resolution, 0.64 mm; NEX, 2; bandwidth, 15.63 Hz; echo-train length, 12). The inversion pulses with the GM sequences were timed so as to reduce the signal intensity of white matter, thus theoretically improving visualization of the LGN. Both the PD and GM sequences were obtained with a homogeneous oblique coronal localizer, in a vertical orientation relative to the long axis of temporal lobe and medial hippocampus on a 3D BRAVO scan. This configuration is demonstrated in Fig 2. The 3D BRAVO sequence required only 2 minutes 40 seconds, much faster than the typically utilized 3D fast-spoiled gradient recalled sequence. This sequence provided sufficient

Fig 1. The pie chart shows the distribution of 52 eyes in 26 patients into different clinical stages.
spatial resolution, though less than the 3D fast-spoiled gradient recalled sequence, to serve as a 3D localizer for the PD and GM sequences.

**Measurement of the LGN**

The LGN is a small nucleus located at the lateral part of the metathalamus, with an internal geniculate nucleus inside. All measurements were made in consensus by 2 neuroradiologists who were blinded to the clinical diagnosis made by the ophthalmologists as detailed previously. Several stipulations on measurement technique were imposed on the readers: All images were magnified to an FOV of 90 × 90 mm² before measurement, the vertical line in height measurements was drawn perpendicular to the base of LGN, and the oblique coronal planes on which the LGN was measured on PD and GM sequences were identical.

Image analyses were performed off-line on an Advantage workstation (AW 4.4; GE Healthcare, Buc, France). For each acquired sequence, LGN height measurements were performed by drawing a vertical line from the apex of the convexity to the base of the LGN as illustrated in Figs 3 and 4. The following measurements were obtained: the maximum PDhR, PDhL, GMhR, and GMhL. LGN volume measurements were performed by using a volume analysis tool available on the off-line workstation. On each scan section on which the LGN was visible, the area of the LGN was measured by using this tool as shown in Fig 5. These measurements were used to compute LGN volumes for the right LGN as obtained with the PDvR and PDvL, as well as the GMvR and GMvL.

All the height and volume measurements were corrected by the width of the temporal horn, an indirect measure of individual head size depicting the regional atrophy in the structures of the medial temporal lobe. Cumulative radius of the left and right temporal horn was calculated. The width of the temporal horn was measured on the GM sequence demonstrated in Fig 6.

**Statistical Analysis**

A general linear model was used to compare measurements of height and volume between the patient and control groups, by using the temporal horn width as a covariate to exclude the effect of head size and global atrophy on LGN size. The confidence intervals of multiple comparisons between patient and control groups were adjusted by the Bonferroni method. Statistical correlation between the height and volume versus the clinical stage of glaucoma was obtained for each eye and for each sequence via the Pearson nonparametric correlation test. The following parameters were also correlated: Sum versus stages L and R as well as stage A. All statistical analysis was performed with standard software (Statistical Package for the Social Sciences, Version 13.0; SPSS, Chicago, Illinois). A P value < .05 was considered statistically significant for all comparisons.

**Results**

Subjectively, delineation of the LGN was much clearer on the GM sequence than on the PD images. This was due to both the improved gray-white matter differentiation with the former and the relatively higher signal intensity of CSF outlining the LGN and the Virchow-Robin spaces in the parenchyma adjoining the LGN. Representative images obtained from both sequences are provided in Fig 7.

Because the section thickness specified in both PD and GM sequences was 1.8 mm, the LGN was typically visible in patients on 3 or 4 oblique corona sequences versus 4 sections in the volunteer group. As measured on the images obtained with the PD sequence, the mean value of the maximum height of the LGN in the patient group was 4.36 ± 0.61 mm on the right and 4.31 ± 0.61 mm on the left. The average measured LGN volume was 98.0 ± 27.2 mm³ on the right and 93.7 ± 25.8 mm³ on the left. For the GM sequence, the corresponding values were respectively 4.20 ± 0.71 mm, 4.00 ± 0.85 mm, 85.2 ± 27.1 mm³, and 80.5 ± 23.6 mm³. There were statistically significant differences between the patient and control groups with both sequences in terms of the maximum LGN height and volume after correction for individual head size (P < 10⁻³, n = 26). These differences are demonstrated in Table 1. Covariates appearing in the model were evaluated at the following value: cumulative temporal horn width = 4.3885. The tests between each variable of LGN size and temporal horn width had homogeneous results: P > .05.

The height and volume of both the right and left LGN as measured on PD and GM sequences were statistically significantly correlated with the cumulative stage of patient disease (stage A) though the r value was not high, ranging from 0.455 to 0.613 (P < .05, n = 26). There was a correlation between stage L and bilateral LGN measurements from both sequences, with the exception of values for right LGN height obtained with the PD sequence (P = .077). The volume of LGN measured with GM images and the height of the right LGN for both sequences were not correlated with the clinical glaucoma stage of the right eye (stage R, P > .05) (Table 2).

**Discussion**

The association between glaucoma and LGN atrophy, while previously demonstrated in animal studies, has only recently been shown in humans. The present study elaborates on this initial observation in a much larger patient cohort and correlates the degree of LGN atrophy to the clinical stage of glaucoma present. This article is the first, to the knowledge of the authors, to show this association, which may have important applications for noninvasive assessment of glaucoma severity. This finding furthermore
suggests that early, as of yet clinically undetected, cases of glaucoma could be incidentally found on MR imaging examinations performed for other purposes, thus potentially facilitating earlier treatment.

This study is also the first to use LGN volume measurements in assessing LGN atrophy. Previous studies have suggested this as an alternative to measuring LGN height because it seems intuitive that a volume measurement accounting for LGN size in 3D would better correlate with glaucoma stage than would a 2D analysis. However, in the present study, it was found that both LGN height and volume correlate well with glaucoma stage. There is clinical value in this observation in that the maximum height measurement is, in practice, more readily obtained than the volume calculations described herein. Given the similar degree of correlation with glaucoma stage, measurements of LGN height would seem to be the preferred alternative for MR imaging assessment of glaucoma. Additionally in the present study, GM and PD-weighted sequences were compared with respect to the correlation of their LGN measurements with clinical stage. Subjectively, the GM images more clearly demarcated the LGN. Specifically, a key anatomic landmark, nearby CSF, was of high signal intensity on the GM sequence, thus improving LGN demarcation.

Suppression of signal intensity from white matter with the GM sequence very likely also improved the accuracy of quantitative measurements due to less gray-white interface blurring; though measurements with both GM and PD sequences correlated equally well with glaucoma stage. Thus, while use of a dedicated GM sequence may aid in the qualitative assessment of the LGN in patients with glaucoma and may improve the precision of measurements obtained, as a practical matter, both PD and GM images do not appear to significantly differ in their correlation with glaucoma stage. Additional assessment of LGN atrophy detection and quantification with more commonly used MR imaging pulse sequences may be of further clinical value.

The interest in MR imaging assessment of glaucoma was spurred by pathologic studies at the level of the LGN and visual cortex, showing a smaller size of the former. These suggested a possible mechanism for neuroradiologic assessment of central visual pathways in glaucoma. Studies in the Japanese monkey glaucoma model further suggested that the magnocellular layer of the LGN may be more vulnerable than the parvocellular layer to the effects of elevated intraocular pressure. Specifically, this study found that layers 1, 4, and 6 of the contralateral LGN and layers 2, 3, and 5 of the ipsilateral LGN receive input from the glaucomatous eye. Additionally, optic chiasm, a well-known anatomic structure, over which the optic nerve crosses, strongly bears out the former finding. In other words, the size of each LGN is reflected by the clinical glaucoma stage of both eyes.

**Fig 3.** PD (left) and GM (right) images obtained in the identical oblique coronal plane demonstrate LGN height measurements in a 43-year-old healthy male volunteer. Specifically, LGN height is determined by drawing a line from the apex of the convexity perpendicular to the base of the LGN. The left image is from the PD sequence, and the right one, from GM sequence.

**Fig 4.** A 36-year-old man with bilateral stage 4 open-angle glaucoma demonstrates bilateral LGN atrophy as shown on both PD (left) and GM (right) sequences.
Analysis of the variables “Sum” and “stage A” were included in the present study to further assess this relationship. On the basis of the data obtained, it appears that there is significant correlation between overall glaucoma stage (Stage A) and LGN size; however, as to stages L and R, there were several variables without significant correlation, though this may be confounded by several factors. For example, there were complex relations between the glaucoma stage in 1 eye versus the size in the contralateral or the ipsilateral LGN. Further study of this observation is thus warranted and may be better assessed in animal models, given the ability to readily obtain pathologic specimens.

MR imaging at 3T was initially applied to assess LGN atrophy in humans though several fMRI studies have evaluated changes in glaucoma. Garaci et al performed a diffusion tensor imaging scan on POAG patients, with MD and FA maps automatically created. They found that the optic radiations and optic nerves of patients with glaucoma, as compared with control subjects, had significantly higher MD and significantly lower FA. Further study showed the mean MD values for the optic nerves and the glaucoma stages varied consistently ($r = 0.8087, P < .0001$) and there was a negative correlation between mean FA for the optic nerves and glaucoma stage ($r = 0.7464, P < .0001$). Duncan et al found the spatial pattern of activity observed in the flattened representation agreed with the pattern of visual field loss and the amplitude of the blood oxygen level-dependent response was correlated on a point-wise basis with the difference in sensitivity thresholds between the glaucomatous and fellow eyes ($r = 0.53, P < .0001$). Additional applications of fMRI, which offer meaningful assessment of neural degeneration and functional alteration are the subject of further work by our laboratory. However, because POAG is an insidious disease, the time of diagnosis does not necessarily coincide with the time of disease onset, rendering disease chronicity difficult to establish. Furthermore, glaucoma that progresses at a variable rate, with fluctuations in intraocular pressure; the timeframe between staging of the glaucomatous disease and neuroimaging may thus not easily be established, especially in the early stage.
The present study has limitations. Although larger than previous studies assessing the relationship in LGN atrophy and glaucoma, the study population used is still relatively small. This may have, for example, affected the statistical power in determining whether volume or height measurements more closely correlated with degree of LGN atrophy. Furthermore, due to the fact that experimentation occurred in human patients, the results of LGN measurements could only be correlated with glaucoma staging rather than pathologic morphology. Although this correlation has been examined extensively in rat and monkey models, the latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.

Table 1: Comparison of LGN size in patients with glaucoma and volunteers as assessed by various parameters a,b

<table>
<thead>
<tr>
<th></th>
<th>PDhR</th>
<th>PDhL</th>
<th>PDvR</th>
<th>PDvL</th>
<th>GMhR</th>
<th>GMhL</th>
<th>GMvR</th>
<th>GMvL</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>.36</td>
<td>.61</td>
<td>.31</td>
<td>.61</td>
<td>.90</td>
<td>.72</td>
<td>.93</td>
<td>.86</td>
<td>95</td>
</tr>
<tr>
<td>Controls</td>
<td>.05</td>
<td>.41</td>
<td>.99</td>
<td>.41</td>
<td>1.43</td>
<td>.23</td>
<td>1.43</td>
<td>.97</td>
<td>131.7</td>
</tr>
</tbody>
</table>

a Covariates appearing in the model are evaluated at the following value: temporal horn width (cumulative) = 4.3865.

Table 2: Correlation between LGN size and glaucoma stage

<table>
<thead>
<tr>
<th>Stage</th>
<th>PDhR</th>
<th>PDhL</th>
<th>PDvR</th>
<th>PDvL</th>
<th>GMhR</th>
<th>GMhL</th>
<th>GMvR</th>
<th>GMvL</th>
<th>Sum</th>
</tr>
</thead>
<tbody>
<tr>
<td>L</td>
<td>.353</td>
<td>.428</td>
<td>.405</td>
<td>.468</td>
<td>.525</td>
<td>.523</td>
<td>.400</td>
<td>.512</td>
<td>.512</td>
</tr>
<tr>
<td>R</td>
<td>.374</td>
<td>.514</td>
<td>.461</td>
<td>.460</td>
<td>.401</td>
<td>.455</td>
<td>.330</td>
<td>.395</td>
<td>.375</td>
</tr>
<tr>
<td>A</td>
<td>.060</td>
<td>.007</td>
<td>.018</td>
<td>.018</td>
<td>.042</td>
<td>.020</td>
<td>.099</td>
<td>.046</td>
<td>.059</td>
</tr>
</tbody>
</table>

Conclusions

The present study confirms the loss in both LGN height and volume in patients with glaucoma and demonstrates that the stage of glaucoma correlates to degree of LGN atrophy. The latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.

The present study has limitations. Although larger than previous studies assessing the relationship in LGN atrophy and glaucoma, the study population used is still relatively small. This may have, for example, affected the statistical power in determining whether volume or height measurements more closely correlated with degree of LGN atrophy. Furthermore, due to the fact that experimentation occurred in human patients, the results of LGN measurements could only be correlated with glaucoma staging rather than pathologic morphology. Although this correlation has been examined extensively in rat and monkey models, the latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.

The present study has limitations. Although larger than previous studies assessing the relationship in LGN atrophy and glaucoma, the study population used is still relatively small. This may have, for example, affected the statistical power in determining whether volume or height measurements more closely correlated with degree of LGN atrophy. Furthermore, due to the fact that experimentation occurred in human patients, the results of LGN measurements could only be correlated with glaucoma staging rather than pathologic morphology. Although this correlation has been examined extensively in rat and monkey models, the latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.

The present study has limitations. Although larger than previous studies assessing the relationship in LGN atrophy and glaucoma, the study population used is still relatively small. This may have, for example, affected the statistical power in determining whether volume or height measurements more closely correlated with degree of LGN atrophy. Furthermore, due to the fact that experimentation occurred in human patients, the results of LGN measurements could only be correlated with glaucoma staging rather than pathologic morphology. Although this correlation has been examined extensively in rat and monkey models, the latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.

The present study has limitations. Although larger than previous studies assessing the relationship in LGN atrophy and glaucoma, the study population used is still relatively small. This may have, for example, affected the statistical power in determining whether volume or height measurements more closely correlated with degree of LGN atrophy. Furthermore, due to the fact that experimentation occurred in human patients, the results of LGN measurements could only be correlated with glaucoma staging rather than pathologic morphology. Although this correlation has been examined extensively in rat and monkey models, the latter fact suggests that a LGN examination by MR imaging may provide a useful noninvasive biomarker for the severity of glaucoma. Furthermore, evaluation of the visual pathways may be useful in the assessment of other degenerative conditions of the eye. However, further longitudinal studies with larger patient cohorts are needed to assess the accuracy of these parameters in determining glaucoma severity. MR imaging measurements of height and volume with the LGN are diminished in patients with glaucoma, with the extent of atrophy correlating to the clinical stage. These findings suggest a novel imaging marker of disease severity.
References